Allogeneic hemopoietic stem cell transplant (HSCT) is a high-risk procedure for development of invasive fungal diseases (IFD) in children. Pre-engraftment neutropenia and severe Graft vs. host disease (GvHD) represent probably the most known, risk factors [1-3], but other factors like age, type of donor, and immunosuppressive therapy have also been reported [1, [3] [4] [5] [6] [7] [8] [9] .
Risk factors associated with development and mortality by invasive fungal diseases in pediatric allogeneic stem cell transplantation. A pediatric subgroup analysis of data from a prospective study of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) Allogeneic hemopoietic stem cell transplant (HSCT) is a high-risk procedure for development of invasive fungal diseases (IFD) in children. Pre-engraftment neutropenia and severe Graft vs. host disease (GvHD) represent probably the most known, risk factors [1] [2] [3] , but other factors like age, type of donor, and immunosuppressive therapy have also been reported [1, [3] [4] [5] [6] [7] [8] [9] . In 2014 the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) published a nationwide prospective survey performed in the period 2008-2010 on risk factors for IFD and IFD-related mortality in the first year after allogeneic HSCT [10] . This original study included both adults and children, but a specific pediatric subpopulation analysis was not performed.
The present study retrospectively analyzed epidemiology, risk factors for IFD, and IFD-related mortality in the subpopulation of patients aging ≤18 years. Results were compared with that of the original study, and not specifically with those strictly observed in adults, that in any case represented near 90% of patients enrolled, suggesting a high strength of the results of that study at least for the adults' population. Data collected and definitions were the same adopted in the original study for IFD, time of occurrence after HSCT and GvHD, as well as for the analyzed variables [10] . However, since the number of patients aging ≤18 years were a fraction (205/1858, 11%) of all included in the original one, some simplifications were introduced in the analyzed variables (underlying disease and its phase, previous HSCT, donor type, type of conditioning regimen, mold active antifungal prophylaxis, status of a pretransplant IFD, center HSCT activity) in order to avoid the presence of categories with too few subjects. Qualitative data were reported as absolute frequencies and percentages and quantitative data as median values and interquartile range (IQR). Cumulative incidence of IFD was calculated considering a possible competing risk of IFD with underlying disease relapse, or death. Overall mortality was estimated by the Kaplan-Meier method and the log-rank test was applied to assess differences between curves. Multivariable analysis was adopted to identify risk factors for IFD and IFD-associated mortality [11] : sub-distribution hazard ratio (SHR) with the 95% confidence interval (CI) was calculated to analyze risk factors and hazard ratio (HR) with 95% for mortality. Likelihood ratio test (LRT) was performed to measure the effect of each predictor. All tests were two-tailed and a p value <0.05 was considered statistically significant. All analyses were performed using Stata (Stata Statistical Software, Release 13 College Station, TX, Stata Corporation, 2013).
A total of 205 allogeneic HSCT procedures were performed in patients aged ≤18 years in 19 Italian centers, with 4 centers performing 74% of transplants. Median age was 11 years (IQR 6-16), 121 (59%) were males. Table 1 summarizes patients' demographic data and the general characteristics of the transplant procedures. Underlying disease was represented by acute leukemia in 47% of cases. About 50% of these diseases were in complete remission. HSCT was performed from a related donor in 43% of cases (70 HLAmatched and 18 HLA mismatched) while the 57% of unrelated donors were represented by a unrelated volunteer in 84 cases and an unrelated cord blood in 33. HSCT source was bone marrow in the majority of procedures (66%). Conditioning regimen was myeloablative in 72% of HSCT, with total body irradiation administered in 34%, while an in vivo T-cell depletion was made in 67%. In 50% of procedures donor had a positive CMV serology and CMV active infection was documented in 34% of cases after HSCT. Finally grades II-IV acute GvHD and extensive chronic GvHD were diagnosed in 40% and 17% of transplants, respectively.
Primary antifungal prophylaxis was administered in 190 (93%) HSCT: 171 (90%) fluconazole, 19 (10%) mold active drugs. Secondary prophylaxis was used in 13 (6%) because of an IFD documented before HSCT, while in 2 (1%) cases no prophylaxis was prescribed.
Overall, 33 IFDs (16% of procedures) were observed. Proven/probable infections (mainly invasive aspergillosis) represented 82% of infections while possible cases were only 18% (Table 1 ). This rate is lower than that reported in other pediatric series, but not too different from the most recent one [2] . This high proportion of proven/probable infections could be due to the more aggressive diagnostic protocols recently adopted also in pediatrics [12] . Noteworthy IFD were mainly observed in late post HSCT periods: 27% of cases in the early (days 1-40), 30% in the late (days 41-100) and 42% very late (days 101-365) post-HSCT phases (Table 1) . This highest frequency in the post engraftment periods is in contrast with what was observed in the original study in which 57% of the cases were observed in the pre-engraftment phase [10] .
The cumulative incidence of IFD was 4.26 (95%CI 1.99-7.83) at 30 days after HSCT; 7.45 (95%CI 4.27-11.77) at 60; 13.29 (95%CI 8.91-18.57) at 120; and 15.96 (95%CI 11.14-21.55) at 270, day of the last IFD diagnosed. These incidences were higher than that observed in the original study [10] . One competing risk was present in 52 (27%) cases. Table 2 reports the results of the univariate and multivariable analysis of risk factors associated with development of IFD and IFD-related mortality. Variables significantly associated with development of IFD were presence of extensive chronic GvHD, use of an alternative donor and CMV reactivation. HSCT from an unrelated donor and presence of extensive chronic GvHD were recognized risk factors also in the original study [10] and have been already reported in pediatrics as associated with IFD [1, 3-6, 13, 14] . Severity of aGvHD was not identified as a significant risk factor for IFD in this study, differently from the original one [10] and other pediatric studies [3, 14] . This could be due to differences in the definitions of GvHD (clinical [2] or temporal [10] ) adopted and/or to the number of pediatric patients analyzed. On the other hand CMV reactivation represented a risk factor for IFD in the pediatric population, [15] but not in the general cohort, even if its effect on IFD has been reported less frequently in adults [16] . In spite of results of other previous studies, [3] age did not represent a risk factor for the development of IFD.
Overall 51 (25%) patients died within 1 year from transplant, 19 (38%) for progression of their underlying disease and 32 (62%) for transplant-related causes. Among the 33 patients with IFD, 10 (30%) died in presence of IFD (proven/probable aspergillosis in 8 cases and possible IFD in 2). In multivariable analysis, the risk of death was significantly associated with a diagnosis of acute leukemia, an underlying disease not in complete remission at HSCT, a non-myeloablative regimen and a diagnosis of IFD after day 40 from HSCT, with a progressive increase of the risk of death moving away from the time of HSCT (considering time as a continuous variable) ( Table 2) . Noteworthy, only the first two variables were significantly associated with death in the general population [10] .
This study has two important limitations. The first is time elapsing from data collection completion and this retrospective analysis. The second is the relatively small number of pediatric patients enrolled in spite of its nationwide and prospective fashion. This could at least partially explain some of the differences we observed between children and adults in the risk factors for development of IFD and related mortality after allogeneic HSCT.
In conclusion, this study allowed a comparison of risk factors for the development of IFD and IFD-associated after allogeneic HSCT between children and adults, that could be useful to understand if data derived from adult cohorts can be used to implement clinical management strategies in children. A similar nationwide study has been recently performed in China [17] , but unfortunately a specific pediatric analysis is not available. Our results showed that there are (obviously) similarities, but also differences that could be only partially explained by the low number of pediatric patients enrolled, and that could be age-specific and clinically relevant, confirming the saying that children are not (simply) small adults. Finally, stemming from these results we could implement the GITMO recommendations prophylaxis of IFD after allogeneic HSCT [18] with specific indications for children: mold active primary antifungal prophylaxis should be administered to pediatric patients with a diagnosis of acute leukemia, transplanted non in complete remission, receiving transplant from an unrelated donor, and when a non-myeloablative conditioning regimen is adopted. This prophylaxis should start after engraftment and in presence of extensive cGvHD, but probably also in presence of severe aGvHD.
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